Keyphrases
C.difficile Infection
100%
Clostridioides
100%
Oral mucosal Vaccine
100%
Enhanced Protection
100%
Difficile
83%
Mouse Model
50%
Antibiotics
33%
Surface Proteins
33%
Nanoparticles
33%
SlpA
33%
Diarrhea
16%
Vancomycin
16%
Anaerobic Organism
16%
Microbiota
16%
Antigen-specific
16%
Bacterial Load
16%
Immunogenicity
16%
Receptor-binding Domain
16%
Healthy Microbiome
16%
Pseudomembranous Colitis
16%
Spore-forming
16%
Clostridioides Difficile
16%
C. Difficile Toxin
16%
TcdB
16%
Antibody Response
16%
IgG Antibody
16%
Metronidazole
16%
Precursor Protein
16%
Hospital-acquired Infection
16%
Specific IgA
16%
IgA Antibody
16%
Fidaxomicin
16%
Serum IgE
16%
Protein Immunogenicity
16%
C. Difficile Toxin B
16%
Target-based Approach
16%
Complete Protection
16%
Oral Vaccine
16%
Asymptomatic Spread
16%
Surface Layer
16%
M-cell Targeting
16%
IgG Response
16%
Resin Column
16%
Nickle
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clostridium Difficile Infection
100%
Mucosal Vaccine
100%
Disease
50%
Mouse Model
50%
Antibiotics
33%
Microflora
33%
Nanoparticle
33%
Immunogenicity
33%
Receptor
16%
Amoxicillin
16%
Diarrhea
16%
Vancomycin
16%
Side Effect
16%
Immunoglobulin G
16%
Pseudomembranous Colitis
16%
Metronidazole
16%
Protein Precursor
16%
Hospital Infection
16%
Oral Vaccine
16%
Fidaxomicin
16%
M-Cell Targeting
16%
Anaerobe
16%
Immunoglobulin A
16%
Medicine and Dentistry
Clostridium Difficile Infection
100%
Mucosal Vaccine
100%
Disease
50%
Antibiotics
33%
Immunogenicity
33%
Nanoparticle
33%
Diarrhea
16%
Vancomycin
16%
Amoxicillin
16%
Gut
16%
Side Effect
16%
Immunoglobulin G
16%
Immunoglobulin A
16%
Metronidazole
16%
Receptor Binding
16%
Antibody Response
16%
Spore
16%
Fidaxomicin
16%
Antigen Specificity
16%
Pseudomembranous Colitis
16%
Oral Vaccine
16%
Hospital Infection
16%
M-Cell Targeting
16%
Protein Precursor
16%